These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12838216)

  • 1. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
    Sherman S; Blaut U; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Earle D; Temkit M; Lehman GA
    Gastrointest Endosc; 2003 Jul; 58(1):23-9. PubMed ID: 12838216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
    Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
    Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis?: a retrospective, multicenter study.
    Deenadayalu VP; Blaut U; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Temkit M; Lehman GA; Sherman S
    J Clin Gastroenterol; 2008; 42(10):1103-9. PubMed ID: 18936645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial.
    Cheon YK; Cho KB; Watkins JL; McHenry L; Fogel EL; Sherman S; Schmidt S; Lazzell-Pannell L; Lehman GA
    Gastrointest Endosc; 2007 Dec; 66(6):1126-32. PubMed ID: 18061712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study.
    Cha SW; Leung WD; Lehman GA; Watkins JL; McHenry L; Fogel EL; Sherman S
    Gastrointest Endosc; 2013 Feb; 77(2):209-16. PubMed ID: 23084272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and predictors of post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction undergoing biliary or dual sphincterotomy: results from the EPISOD prospective multicenter randomized sham-controlled study.
    Yaghoobi M; Pauls Q; Durkalski V; Romagnuolo J; Fogel EL; Tarnasky PR; Aliperti G; Freeman ML; Kozarek RA; Jamidar PA; Wilcox CM; Elta GH; Hawes RH; Wood-Williams A; Cotton PB
    Endoscopy; 2015 Oct; 47(10):884-90. PubMed ID: 26165739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis.
    Mosler P; Sherman S; Marks J; Watkins JL; Geenen JE; Jamidar P; Fogel EL; Lazzell-Pannell L; Temkit M; Tarnasky P; Block KP; Frakes JT; Aziz AA; Malik P; Nickl N; Slivka A; Goff J; Lehman GA
    Gastrointest Endosc; 2005 Aug; 62(2):245-50. PubMed ID: 16046988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis.
    Madácsy L; Kurucsai G; Fejes R; Székely A; Székely I
    Dig Endosc; 2009 Jan; 21(1):8-13. PubMed ID: 19691794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
    Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
    World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
    Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
    Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification.
    Cheon YK; Cho KB; Watkins JL; McHenry L; Fogel EL; Sherman S; Lehman GA
    Gastrointest Endosc; 2007 Mar; 65(3):385-93. PubMed ID: 17321236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
    Budzyńska A; Marek T; Nowak A; Kaczor R; Nowakowska-Dulawa E
    Endoscopy; 2001 Sep; 33(9):766-72. PubMed ID: 11558030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial.
    Oh HC; Cheon YK; Cho YD; Do JH
    Gastrointest Endosc; 2011 Sep; 74(3):556-62. PubMed ID: 21802079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis.
    Rabenstein T; Fischer B; Wiessner V; Schmidt H; Radespiel-Tröger M; Hochberger J; Mühldorfer S; Nusko G; Messmann H; Schölmerich J; Schulz HJ; Schönekäs H; Hahn EG; Schneider HT
    Gastrointest Endosc; 2004 May; 59(6):606-13. PubMed ID: 15114301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for post-ERCP pancreatitis in high risk patients who have undergone prophylactic pancreatic duct stenting: a multicenter retrospective study.
    Ito K; Fujita N; Kanno A; Matsubayashi H; Okaniwa S; Nakahara K; Suzuki K; Enohara R;
    Intern Med; 2011; 50(24):2927-32. PubMed ID: 22185981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Needle-knife sphincterotomy: factors predicting its use and the relationship with post-ERCP pancreatitis (with video).
    Bailey AA; Bourke MJ; Kaffes AJ; Byth K; Lee EY; Williams SJ
    Gastrointest Endosc; 2010 Feb; 71(2):266-71. PubMed ID: 20003969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone.
    Fogel EL; Eversman D; Jamidar P; Sherman S; Lehman GA
    Endoscopy; 2002 Apr; 34(4):280-5. PubMed ID: 11932782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial.
    Katsinelos P; Kountouras J; Chatzis J; Christodoulou K; Paroutoglou G; Mimidis K; Beltsis A; Zavos C
    Gastrointest Endosc; 2005 Mar; 61(3):407-15. PubMed ID: 15758912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography.
    Kawaguchi Y; Ogawa M; Omata F; Ito H; Shimosegawa T; Mine T
    World J Gastroenterol; 2012 Apr; 18(14):1635-41. PubMed ID: 22529693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.